Open Orphan (LON:ORPH) Completion of the compulsory acquisition of remaining hVIVO shares.

Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, announces that further to the announcement of 28 January 2020.

The Company will shortly be posting letters to shareholders of hVIVO plc (“hVIVO”) who did not accept the offer made by the Company on 9 December 2019. The letters confirm completion of the compulsory acquisition of all remaining hVIVO shares (the “Compulsory Acquisition”), which occurred today, pursuant to the provisions of sections 974-991 of the Companies Act 2006.

Application has been made to AIM for 15,600,932 ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) to be admitted to trading on AIM and Euronext Growth (“Admission”). Admission is expected to occur at 8.00 a.m. on 12 March 2020. The allotment and issue of these consideration shares to the non-assenting shareholders pursuant to the Compulsory Acquisition will be the final tranche of shares to be issued in respect of the merger with hVIVO, which completed on 17 January 2020.

Total Voting Rights

In conformity with the FCA’s Disclosure Guidance and Transparency Rules, the Company confirms that following Admission, its issued share capital will consist of 549,038,274 Ordinary Shares. All of the Ordinary Shares have equal voting rights and there are no Ordinary Shares held in treasury. This figure of 549,038,274 Ordinary Shares represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates.

Terms of Website Use

All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Share via
Copy link
Malcare WordPress Security